Agreed. Today's unexpected PR gives great hope for future products that we don't have to wait 2 years for as RGBP moves to partnerships with established and respected entities to move its development forward.
NIH/NCATS also is set up to license any prospective compounds to big pharma, so in my view, this is another positive where big pharma can license an RGBP NR2F6 possible compound via NCAT with RGBP benefitting financially. And who knows, if they discover multiple possible compounds, we could get either a bidding war for someone to license them all our they can sell each possible compound to a different Pharmaceutical company and reap the benefits.
We were waiting almost 3 years for HemaX news. Today's news was unexpected - just can't understand lack of volume at all.
News 
Market Data 
Discover 
AI
